Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) have earned an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $55.2857.

KNSA has been the subject of several recent research reports. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, January 22nd. Canaccord Genuity Group began coverage on Kiniksa Pharmaceuticals International in a research note on Thursday, February 19th. They set a “buy” rating and a $62.00 price objective for the company. Wedbush increased their price objective on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Finally, Zacks Research upgraded Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th.

Kiniksa Pharmaceuticals International Price Performance

KNSA stock opened at $45.78 on Monday. The company has a market cap of $3.50 billion, a price-to-earnings ratio of 61.86 and a beta of 0.06. The company has a fifty day moving average price of $43.83 and a 200 day moving average price of $40.77. Kiniksa Pharmaceuticals International has a 12 month low of $18.25 and a 12 month high of $49.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.12). The business had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $200.86 million. Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The company’s revenue for the quarter was up 65.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.12) earnings per share. As a group, analysts anticipate that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, Director Barry D. Quart sold 2,690 shares of the business’s stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $45.00, for a total value of $121,050.00. Following the transaction, the director directly owned 12,546 shares of the company’s stock, valued at approximately $564,570. The trade was a 17.66% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Mark Ragosa sold 17,845 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $43.28, for a total transaction of $772,331.60. Following the transaction, the chief financial officer owned 12,086 shares of the company’s stock, valued at approximately $523,082.08. The trade was a 59.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 48,605 shares of company stock valued at $2,122,646. Corporate insiders own 53.48% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently made changes to their positions in KNSA. USA Financial Formulas purchased a new position in Kiniksa Pharmaceuticals International during the third quarter worth about $32,000. Smartleaf Asset Management LLC purchased a new stake in Kiniksa Pharmaceuticals International in the 4th quarter valued at approximately $36,000. EverSource Wealth Advisors LLC boosted its holdings in Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares in the last quarter. Nano Cap New Millennium Growth Fund L P acquired a new position in Kiniksa Pharmaceuticals International during the 4th quarter worth approximately $41,000. Finally, CIBC Private Wealth Group LLC acquired a new position in Kiniksa Pharmaceuticals International during the 4th quarter worth approximately $41,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.